Pharming to acquire ProBio International

Published: 6-Jan-2005

Pharming Group is to acquire biotech company ProBio International Holdings.


Pharming Group is to acquire biotech company ProBio International Holdings.

The acquisition expands the commercial opportunities for Pharming with recombinant human lactoferrin and enhances its protein production technology platform.

Dutch protein therapeutics specialist Pharming previously had a 45% shareholding in ProBio, and through the acquisition will gain control of the intellectual property portfolio and rights to the non-pharmaceutical applications of recombinant human lactoferrin. In addition, it will benefit from the relationships of ProBio with pan-Asian entities, including the governments of Singapore, Australia and New Zealand.

Detailed financial terms of the acquisition have not been disclosed.

  • Companies:
  • Pharming
See more

You may also like

Ingredients

Therapeutic: leniolisib for APDS

Read more
APDS or activated phosphoinositide 3-kinase delta (PI3K∂) syndrome is an ultra-rare primary immunodeficiency disease

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  3. ISPE announces 2024 Facility of the Year Awards category winners The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be complicated. Here, the tablet experts Natoli explain how to develop tabletability, compactibility, and compressibility profiles
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Ingredients

Therapeutic: leniolisib for APDS

APDS or activated phosphoinositide 3-kinase delta (PI3K∂) syndrome is an ultra-rare primary immunodeficiency disease
Research & Development

Pharming enrols first patient in Ruconest COVID-19 study

It follows a study into the use of Ruconest in the prevention of severe SARS-CoV-2 infections in patients hospitalised with related severe pneumonia
Finance

Pharming to build downstream processing facility in Oss

The facility will process the starting material for the company’s Ruconest product
Regulatory

FDA approves new facility for Pharming Group biologic production

Netherlands-based pharmaceutical company has received approval to expand production of angioedema biologic in the Netherlands
Regulatory

European Commission amends Marketing Authorisation for RUCONEST to include self-administration

Pharming Group N.V. has announced that, following the positive opinion of the Committee for Medicinal Products for Human Use (CHMP), the European Commission has adopted the Commission Implementing Decision to amend the marketing authorisation for RUCONEST® to include self administration using the RUCONEST® Administration Kit.
Research & Development

Pharming announces completion of financing for RUCONEST North American Rights Acquisition

Pharming Group N.V. has announced that it has closed a new financing round, comprising three financial instruments and a rights issue, providing a total of €104 million before costs.
Research & Development

Pharming agrees collaboration with Shanghai Institute of Pharmaceutical Industry (SIPI)

Pharming also grants SIPI exc;usive licence to Ruconest in China
Subscribe now